FDA still vague over US biosimilars pathway as Abbott ‘pleads the Fifth’
This article was originally published in Scrip
Executive Summary
For a law that is supposed to open the door to cheaper versions of branded biologic medicines, the US biosimilars legislation is turning out to be surprisingly vague in a number of respects, to the extent that it could undermine confidence in the new biosimilar approval pathway.